首页|The recent advancement of TCR-T cell therapies for cancer treatment
The recent advancement of TCR-T cell therapies for cancer treatment
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
Adoptive cell therapies involve infusing engineered immune cells into cancer patients to recognize and eliminate tumor cells.Adoptive cell therapy,as a form of living drug,has undergone explosive growth over the past decade.The recognition of tumor antigens by the T-cell receptor(TCR)is one of the natural mechanisms that the immune system used to eliminate tumor cells.TCR-T cell therapy,which involves introducing exogenous TCRs into patients'T cells,isa novel cell therapy strategy.TCR-T celltherapy can target the entire proteome of cancer cells.Engineering T cells with exogenous TCRs to help patients combat cancer has achieved success in clinical trials,particularly in treating solid tumors.In this review,we examine the progress of TCR-T cell therapy over the past five years.This includes the discovery of new tumor antigens,protein engineering techniques for TCR,reprogramming strategies for TCR-T cell therapy,clinical studies on TCR-T cell therapy,and the advancement of TCR-T cell therapy in China,We also propose several potential directions for the future development of TCR-T cell therapy.
Key Laboratory of Multi-Cell Systems,Shanghai Institute of Biochemistry and Cell Biology,Center for Excellence in Molecular Cell Science,Chinese Academy of Sciences,Shanghai 200031,China
startup funding from the Center for Excellence in Molecular Cell Science at the Chinese Academy of Science国家自然科学基金上海市浦江人才计划
NETL
NSTL
万方数据
